Movement Alert｜Duality Biotherapeutics-B Rises 5.65% in Regular Trading, Buyback Action Signals Management Confidence Amid Biotech Rebound

Market Focus06-29

On June 29, Duality Biotherapeutics-B rose 5.65% in regular trading, trading at HK$173.1/share, with turnover of HK$31.49 million.

On the news front, the company disclosed on June 29 that it repurchased 73,800 shares on June 26 at prices ranging from HK$161.20 to HK$164.40 per share, spending approximately HK$11.99 million. The buyback came after the stock fell 5.18% on June 26 amid broad sector pressure, indicating management actively supporting the share price at lower levels. Additionally, shareholders approved a new buyback authorization at the annual general meeting on June 26, permitting repurchases of up to 9.058 million shares.

At the industry level, the biotech sector saw a broad rebound, with TransThera-B up 20.0%, Remegen up 6.46%, Akeso up 4.5%, Innovent Bio up 2.59%, and BeiGene up 1.75%, creating notable sector-wide momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1130031573?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-29 09:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130031573","market":"us","top_or_hot":-1,"title":"Movement Alert｜Duality Biotherapeutics-B Rises 5.65% in Regular Trading, Buyback Action Signals Management Confidence Amid Biotech Rebound","media":"Market Focus","content":"<p><p>On June 29, Duality Biotherapeutics-B rose 5.65% in regular trading, trading at HK$173.1/share, with turnover of HK$31.49 million.</p><p>On the news front, the company disclosed on June 29 that it repurchased 73,800 shares on June 26 at prices ranging from HK$161.20 to HK$164.40 per share, spending approximately HK$11.99 million. The buyback came after the stock fell 5.18% on June 26 amid broad sector pressure, indicating management actively supporting the share price at lower levels. Additionally, shareholders approved a new buyback authorization at the annual general meeting on June 26, permitting repurchases of up to 9.058 million shares.</p><p>At the industry level, the biotech sector saw a broad rebound, with TransThera-B up 20.0%, Remegen up 6.46%, Akeso up 4.5%, Innovent Bio up 2.59%, and BeiGene up 1.75%, creating notable sector-wide momentum.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Duality Biotherapeutics-B Rises 5.65% in Regular Trading, Buyback Action Signals Management Confidence Amid Biotech Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Duality Biotherapeutics-B Rises 5.65% in Regular Trading, Buyback Action Signals Management Confidence Amid Biotech Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-29 09:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 29, Duality Biotherapeutics-B rose 5.65% in regular trading, trading at HK$173.1/share, with turnover of HK$31.49 million.</p><p>On the news front, the company disclosed on June 29 that it repurchased 73,800 shares on June 26 at prices ranging from HK$161.20 to HK$164.40 per share, spending approximately HK$11.99 million. The buyback came after the stock fell 5.18% on June 26 amid broad sector pressure, indicating management actively supporting the share price at lower levels. Additionally, shareholders approved a new buyback authorization at the annual general meeting on June 26, permitting repurchases of up to 9.058 million shares.</p><p>At the industry level, the biotech sector saw a broad rebound, with TransThera-B up 20.0%, Remegen up 6.46%, Akeso up 4.5%, Innovent Bio up 2.59%, and BeiGene up 1.75%, creating notable sector-wide momentum.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"","article_id":"1130031573","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130031573","pubTimestamp":1782698254,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 29, Duality Biotherapeutics-B rose 5.65% in regular trading, trading at HK$173.1/share, with turnover of HK$31.49 million.On the news front, the company disclosed on June 29 that it...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B"},"translate_title":"动向提示|Duality Biotherapeutics-B在常规交易中上涨5.65%，回购行动表明管理层在生物技术反弹中的信心","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"On June 29, Duality Biotherapeutics-B rose 5.65% in regular trading, trading at HK$173.1/share, with turnover of HK$31.49 million.On the news front, the company disclosed on June 29 that it repurchased 73,800 shares on June 26 at prices ranging from HK$161.20 to HK$164.40 per share, spending approximately HK$11.99 million. The buyback came after the stock fell 5.18% on June 26 amid broad sector pressure, indicating management actively supporting the share price at lower levels. Additionally, shareholders approved a new buyback authorization at the annual general meeting on June 26, permitting repurchases of up to 9.058 million shares.At the industry level, the biotech sector saw a broad rebound, with TransThera-B up 20.0%, Remegen up 6.46%, Akeso up 4.5%, Innovent Bio up 2.59%, and BeiGene up 1.75%, creating notable sector-wide momentum.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1130031573","isCrawlerRequest":true}